Kidney function and prescribed dose in middle-aged and older patients starting selective serotonin reuptake inhibitors

被引:3
作者
Zhu, Nanbo [1 ]
Lisinski, Alexander [2 ]
Lagerberg, Tyra [1 ]
Johnell, Kristina [1 ]
Xu, Hong [3 ]
Carrero, Juan Jesus [1 ]
Chang, Zheng [1 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, Nobels vag 12A, S-17177 Stockholm, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Gothenburg, Sweden
[3] Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
chronic kidney disease; dose adjustment; estimated glomerular filtration rate; prescribed dose; selective serotonin reuptake inhibitors; MAJOR DEPRESSIVE DISORDER; DISEASE; ASSOCIATION; ANTIDEPRESSANTS; MANAGEMENT; METAANALYSIS; PREVALENCE; GUIDELINES; EXPERIENCE; SERTRALINE;
D O I
10.1002/pds.5515
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To avoid adverse drug reactions, dose reductions are recommended when prescribing selective serotonin reuptake inhibitors (SSRIs) to patients with impaired kidney function. The extent of this practice in routine clinical care is however unknown. We aimed to evaluate the starting and maintenance SSRI doses prescribed to patients stratified by levels of kidney function in real-world practice. Methods Using data from the Stockholm CREAtinine Measurements (SCREAM) project, we identified 101 409 new users of antidepressants (including 52 286 SSRI users) in the region of Stockholm during 2006-2019, who were >= 50 years of age and had a recent creatinine test taken in order to estimate glomerular filtration rate (eGFR). SSRI dose reduction was defined as a prescribed SSRI dose of <= 0.5 defined daily doses, according to current recommendations. We examined the associations between eGFR and reductions in initial dose and maintenance dose of SSRIs using logistic regression models. Results Overall, reductions in initial and maintenance dose were observed among 54.1% and 34.1% of new SSRI users. Nevertheless, about 40% of individuals with an eGFR <30 ml/min/1.73 m(2) were prescribed an SSRI without dose reduction. After adjusting for age and other covariates, lower eGFR was associated with moderately higher odds of dose reduction, for both initial and maintenance dose. Compared to individuals with an eGFR of 90-104 ml/min/1.73 m(2), the adjusted odds ratios for those with an eGFR <30 ml/min/1.73 m(2) were 1.18 (95% CI: 1.03, 1.36) for initial dose reduction, and 1.49 (1.29, 1.72) for maintenance dose reduction. Stratified analyses showed stronger associations between lower eGFR and SSRI dose reduction among individuals aged 50-64 years and in those receiving prescriptions from psychiatric care. Conclusions Lower kidney function was moderately associated with a reduced SSRI dose, independently of age. Prescribing SSRIs to middle-aged and older patients should not only consider patients' age but also their kidney function.
引用
收藏
页码:1091 / 1101
页数:11
相关论文
共 43 条
[1]   Drugs for Depression (Reprinted from Medical Letter on Drugs and Therapeutics, vol 62, pg 25-32, 2020) [J].
Livingston, Edward .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (21) :2188-2189
[2]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[3]  
[Anonymous], 2010, DEPR AD CHRON PHYS H
[4]  
Ashley C, 2019, The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners, V5th
[5]   Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis [J].
Assimon, Magdalene M. ;
Brookhart, M. Alan ;
Flythe, Jennifer E. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (04) :611-623
[6]   Depression and chronic kidney disease: A review for clinicians [J].
Bautovich, Alison ;
Katz, Ivor ;
Smith, Michelle ;
Loo, Colleen K. ;
Harvey, Samuel B. .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 (06) :530-541
[7]   Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].
Bikbov, Boris ;
Purcell, Carrie ;
Levey, Andrew S. ;
Smith, Mari ;
Abdoli, Amir ;
Abebe, Molla ;
Adebayo, Oladimeji M. ;
Afarideh, Mohsen ;
Agarwal, Sanjay Kumar ;
Agudelo-Botero, Marcela ;
Ahmadian, Elham ;
Al-Aly, Ziyad ;
Alipour, Vahid ;
Almasi-Hashiani, Amir ;
Al-Raddadi, Rajaa M. ;
Alvis-Guzman, Nelson ;
Amini, Saeed ;
Andrei, Tudorel ;
Andrei, Catalina Liliana ;
Andualem, Zewudu ;
Anjomshoa, Mina ;
Arabloo, Jalal ;
Ashagre, Alebachew Fasil ;
Asmelash, Daniel ;
Ataro, Zerihun ;
Atout, Maha Moh'd Wahbi ;
Ayanore, Martin Amogre ;
Badawi, Alaa ;
Bakhtiari, Ahad ;
Ballew, Shoshana H. ;
Balouchi, Abbas ;
Banach, Maciej ;
Barquera, Simon ;
Basu, Sanjay ;
Bayih, Mulat Tirfie ;
Bedi, Neeraj ;
Bello, Aminu K. ;
Bensenor, Isabela M. ;
Bijani, Ali ;
Boloor, Archith ;
Borzi, Antonio M. ;
Camera, Luis Alberto ;
Carrero, Juan J. ;
Carvalho, Felix ;
Castro, Franz ;
Catala-Lopez, Ferran ;
Chang, Alex R. ;
Chin, Ken Lee ;
Chung, Sheng-Chia ;
Cirillo, Massimo .
LANCET, 2020, 395 (10225) :709-733
[8]   Metabolism of the newer antidepressants - An overview of the pharmacological and pharmacokinetic implications [J].
Caccia, S .
CLINICAL PHARMACOKINETICS, 1998, 34 (04) :281-302
[9]   The Stockholm CREAtinine Measurements (SCREAM) project: Fostering improvements in chronic kidney disease care [J].
Carrero, Juan Jesus ;
Elinder, Carl Gustaf .
JOURNAL OF INTERNAL MEDICINE, 2022, 291 (03) :254-268
[10]   Update on psychotropic medication use in renal disease [J].
Cohen, LM ;
Tessier, EG ;
Germain, MJ ;
Levy, NB .
PSYCHOSOMATICS, 2004, 45 (01) :34-48